For the media:
Shortage Drug Compounding and GLP-1s: What you need to know

☞ On deadline? For media inquiries CLICK HERE. 

Upcoming Events

October 29: PCAC meeting on adding several bulk drug substances to the 503A Bulks List (1 of 2)

November 7: APC CE webinar: Preservatives in Pharmacy Compounding

November 14: ARL Bio Pharma free CE webinar: Peering Beyond the Chapter: Elevating Sterile Compounding Practices

November 15-17: Personalized Medicine Certification Course 1: Endocrinology, virtual

December 4:  PCAC meeting on adding several bulk drug substances to the 503A Bulks List (2 of 2)

December 5: APC CE webinar: Compounding in Special Populations

December 5: CompoundED UpDATE Regional Meeting, Scottsdale, AZ

December 13: APC Board of Directors Meeting, Las Vegas

December 13-15: A4M Longevity Fest, Las Vegas

APC In the News

PharmExec features APC execs talking about the compounding process:

From the manufacturing process to patient and provider challenges, this PharmExec video interview covers all things compounding.

APC calls out Novo in Reuters:

Reuters used our comment that there's a difference between making molecules and compounding with them.

CBS quotes APC on resolving shortages:

Taking a different angle, this article looked how the FDA decides when to resolve a shortage.

The Brits could have done better:

UK-based pharmaphorum is covering the GLP-1 issue, but it played down our rather important point about the ease of compounding with the drugs.

Video: APC on Scripps:

APC CEO Scott Brunner appeared on the Scripps News show “America On The Docket,” talking about the “brewing legal battle” over compounded tirzepatide and semaglutide.

Tirzepatide fallout in The Hill:

The Hill writes one of the first stories on the fallout from the FDA's tirzepatide decision.

Echoing our position:

Specialty Pharmacy Continuum has a great piece on the importance of a longer "tail" for 503As.

Wired story isn’t perfect, but…:

This time Wired missed the mark on pharmacy compounding, but it at least quoted Scott and focused on the important issues.

Wired focuses on GLP-1 patient fallout:

Wired looks at how some patients are being hit hard by tirzepatide coming off shortage.

Quartz mentions APC:

Not a big deal, but it shows we're getting media coverage across the spectrum.

San Diego news radio focuses on GLP-1 price:

It could have chosen any angle, and it went with the high price of commercial versions. 👍🏻

CNN gets it spot on:

The article, which of course quotes APC, focuses on the impact on patients of tirzepatide coming out of shortage.

Click here for more examples of APC in the news

Support Compounding

Our Patrons